T‐Cell Immunity and Lung Cancer
Respirology · 2026
DOI: 10.1002/resp.70220 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Respirology, 2026. Verfasst von Kotaro Yamada und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan. Hauptthemen laut MEDLINE: Lung Neoplasms, T-Lymphocytes. Die Arbeit nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AMED, Japan Society for the Promotion of Science, Fusion Oriented REsearch for disruptive Science and Technology, FOREST.
Abstract (Originalsprache)
Lung cancer remains a leading cause of cancer mortality worldwide. Although immune checkpoint inhibitors (ICIs) have reshaped therapeutic strategies in lung cancer, their benefits remain limited. ICIs exert their therapeutic efficacy by activating T‐cell effector functions, underscoring the central role of T cells in antitumor immunity. Thus, this review focuses on the role of T cells in lung cancer and summarises recent advances. Tumour‐specific CD8 + T cells that attack tumour cells directly form the core of antitumor immunity, yet chronic antigenic stimulation drives functional impairment and exhaustion that constrain treatment responsiveness. Conversely, regulatory T cells modulate immune responses through diverse suppressive mechanisms and influence clinical outcomes. In addition, tertiary lymphoid structures (TLSs) that arise within tumours can amplify local immunity through interactions among follicular helper T cells, B cells, and other immune subsets, and are increasingly linked to therapeutic efficacy and prognosis. Emerging evidence also indicates that metabolic features of the tumour microenvironment modulate T‐cell differentiation and persistence. Collectively, these insights provide a foundation for translating an improved understanding of T‐cell–centred immune responses and their regulatory circuits into clinical practice. Overall, clarifying T‐cell functional states is essential for optimising immunotherapy and achieving durable benefit in lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
- Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
- Faculty of Medicine, Kindai University, Osaka, Japan.
ORCID-Profile: Yosuke Togashi
Förderung
- AMED
- Japan Society for the Promotion of Science
- Fusion Oriented REsearch for disruptive Science and Technology, FOREST
- Japan Agency for Medical Research and Development
- Fusion Oriented REsearch for disruptive Science and Technology
Zitieren
APA
Yamada, K., & Togashi, Y. (2026). T‐Cell Immunity and Lung Cancer. Respirology. https://doi.org/10.1002/resp.70220
Vancouver
Yamada K, Togashi Y. T‐Cell Immunity and Lung Cancer. Respirology. 2026. doi:10.1002/resp.70220
BibTeX
@article{Yamada2026,
author = {Yamada, Kotaro and Togashi, Yosuke},
title = {T‐Cell Immunity and Lung Cancer},
journal = {Respirology},
year = {2026},
doi = {10.1002/resp.70220}
}
EUVIMED